Drugs / HeXell-2020
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07144072 | Jan 2026 → Jan 2028 expected | — | Hexun Biosciences Co., LTD. | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07137104 | Dec 2025 → Dec 2027 expected | coronary artery disorder | Hexun Biosciences Co., LTD. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HeXell-2020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07144072 ↗ |
| Modality | Cell therapy | “allogenic umbilical cord mesenchymal stem cells (UCMSCs) as the drug substance” NCT07137104 ↗ |
| Route | Intravenous | “HeXell-2020 will be administered by intravenous once every two weeks” NCT07137104 ↗ |